deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00729612

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase II Trial of Abraxane Plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding From VEGF Directed Therapies

Sponsor: Celgene Corporation

Conditions Lung Cancer
Interventions carboplatin immunoenzyme technique immunohistochemistry staining method laboratory biomarker analysis paclitaxel albumin-stabilized nanoparticle formulation protein expression analysis
Updated 7 times since 2017 Last updated: Mar 6, 2018 Started: Aug 14, 2008 Primary completion: Dec 16, 2011 Completion: Dec 16, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lung Cancer and is currently completed. Celgene Corporation leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~May 2018 · 15 months · monthly snapshotActive Not Recruiting~May 2018 – ~Jun 2018 · 31 days · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. May 2018 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 2 earlier versions

  1. Feb 2017 — May 2018 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celgene Corporation
  • Greg Otterson
  • National Comprehensive Cancer Network
Data source: Ohio State University Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations